FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151122755> ?p ?o ?g. }

• W2151122755 endingPage "S44" @default.
• W2151122755 startingPage "S44" @default.
• W2151122755 abstract "PurposeManagement of spinal neoplasms has relied on open surgery and external beam radiotherapy (EBRT). Although primary spinal tumors are rare, their treatment remains a pervasive problem. This analysis sought to evaluate the safety and efficacy of CT-guided 125I seed brachytherapy for recurrent paraspinous and vertebral primary tumors.Materials and MethodsFrom November 2002 to June 2014, 17 patients who met the inclusion criteria were retrospectively reviewed. 14 (82.4%) had previously undergone surgery, 15 (88.2%) had received conventional EBRT and 3 (17.6%) had chosen chemotherapy. The number of 125I seeds implanted ranged from 7 to 122 (median 79) with specific activity of 0.5-0.8 mCi (median 0.7 mCi). The post-plan showed that the actuarial D90 of 125I seeds were 90-183 Gy (median 137 Gy). The follow-up period ranged from 2 to 69 (median 19 months). The local control probabilities were calculated by the Kaplan-Meier method.ResultsFor 5 Chondrosarcomas, the 1, 2, 3 year local control rate were 75%, 37.5%, and 37.5% respectively, with a median of 34 months (range, 4-39 months). For 4 chordomas, the olcal control rate was 50% with a median follow-up of 13 months (range, 3-17 months). For 3 fibromatosis, all of them were survival without local recurrence at the end of follow-up. During the follow-up period, 35.3% (6/17) died from metastases, 17.6% (3/17) developed local recurrence by 8, 14 and 34 months while 64.7% (11/17) remained alive. 100% experienced pain relief and normal or improved ambulation without more than Frankel grade 3 radiation myelopathy.ConclusionsPercutaneous 125I seed implantation can be an alternative or retreatment for recurrent spinal primary tumors. PurposeManagement of spinal neoplasms has relied on open surgery and external beam radiotherapy (EBRT). Although primary spinal tumors are rare, their treatment remains a pervasive problem. This analysis sought to evaluate the safety and efficacy of CT-guided 125I seed brachytherapy for recurrent paraspinous and vertebral primary tumors. Management of spinal neoplasms has relied on open surgery and external beam radiotherapy (EBRT). Although primary spinal tumors are rare, their treatment remains a pervasive problem. This analysis sought to evaluate the safety and efficacy of CT-guided 125I seed brachytherapy for recurrent paraspinous and vertebral primary tumors. Materials and MethodsFrom November 2002 to June 2014, 17 patients who met the inclusion criteria were retrospectively reviewed. 14 (82.4%) had previously undergone surgery, 15 (88.2%) had received conventional EBRT and 3 (17.6%) had chosen chemotherapy. The number of 125I seeds implanted ranged from 7 to 122 (median 79) with specific activity of 0.5-0.8 mCi (median 0.7 mCi). The post-plan showed that the actuarial D90 of 125I seeds were 90-183 Gy (median 137 Gy). The follow-up period ranged from 2 to 69 (median 19 months). The local control probabilities were calculated by the Kaplan-Meier method. From November 2002 to June 2014, 17 patients who met the inclusion criteria were retrospectively reviewed. 14 (82.4%) had previously undergone surgery, 15 (88.2%) had received conventional EBRT and 3 (17.6%) had chosen chemotherapy. The number of 125I seeds implanted ranged from 7 to 122 (median 79) with specific activity of 0.5-0.8 mCi (median 0.7 mCi). The post-plan showed that the actuarial D90 of 125I seeds were 90-183 Gy (median 137 Gy). The follow-up period ranged from 2 to 69 (median 19 months). The local control probabilities were calculated by the Kaplan-Meier method. ResultsFor 5 Chondrosarcomas, the 1, 2, 3 year local control rate were 75%, 37.5%, and 37.5% respectively, with a median of 34 months (range, 4-39 months). For 4 chordomas, the olcal control rate was 50% with a median follow-up of 13 months (range, 3-17 months). For 3 fibromatosis, all of them were survival without local recurrence at the end of follow-up. During the follow-up period, 35.3% (6/17) died from metastases, 17.6% (3/17) developed local recurrence by 8, 14 and 34 months while 64.7% (11/17) remained alive. 100% experienced pain relief and normal or improved ambulation without more than Frankel grade 3 radiation myelopathy. For 5 Chondrosarcomas, the 1, 2, 3 year local control rate were 75%, 37.5%, and 37.5% respectively, with a median of 34 months (range, 4-39 months). For 4 chordomas, the olcal control rate was 50% with a median follow-up of 13 months (range, 3-17 months). For 3 fibromatosis, all of them were survival without local recurrence at the end of follow-up. During the follow-up period, 35.3% (6/17) died from metastases, 17.6% (3/17) developed local recurrence by 8, 14 and 34 months while 64.7% (11/17) remained alive. 100% experienced pain relief and normal or improved ambulation without more than Frankel grade 3 radiation myelopathy. ConclusionsPercutaneous 125I seed implantation can be an alternative or retreatment for recurrent spinal primary tumors. Percutaneous 125I seed implantation can be an alternative or retreatment for recurrent spinal primary tumors." @default.
• W2151122755 created "2016-06-24" @default.
• W2151122755 creator A5003360183 @default.
• W2151122755 creator A5012911609 @default.
• W2151122755 creator A5031391047 @default.
• W2151122755 creator A5050185265 @default.
• W2151122755 creator A5063671035 @default.
• W2151122755 creator A5086284220 @default.
• W2151122755 creator A5088844549 @default.
• W2151122755 creator A5090219433 @default.
• W2151122755 date "2015-05-01" @default.
• W2151122755 modified "2023-10-12" @default.
• W2151122755 title "CT-Guidance Interstitial 125iodine Seed Brachytherapy as a Salvage Therapy for Recurrent Spinal Primary Tumors" @default.
• W2151122755 doi "https://doi.org/10.1016/j.brachy.2015.02.264" @default.
• W2151122755 hasPublicationYear "2015" @default.
• W2151122755 type Work @default.
• W2151122755 sameAs 2151122755 @default.
• W2151122755 citedByCount "1" @default.
• W2151122755 countsByYear W21511227552023 @default.
• W2151122755 crossrefType "journal-article" @default.
• W2151122755 hasAuthorship W2151122755A5003360183 @default.
• W2151122755 hasAuthorship W2151122755A5012911609 @default.
• W2151122755 hasAuthorship W2151122755A5031391047 @default.
• W2151122755 hasAuthorship W2151122755A5050185265 @default.
• W2151122755 hasAuthorship W2151122755A5063671035 @default.
• W2151122755 hasAuthorship W2151122755A5086284220 @default.
• W2151122755 hasAuthorship W2151122755A5088844549 @default.
• W2151122755 hasAuthorship W2151122755A5090219433 @default.
• W2151122755 hasConcept C141071460 @default.
• W2151122755 hasConcept C2777416452 @default.
• W2151122755 hasConcept C509974204 @default.
• W2151122755 hasConcept C71924100 @default.
• W2151122755 hasConceptScore W2151122755C141071460 @default.
• W2151122755 hasConceptScore W2151122755C2777416452 @default.
• W2151122755 hasConceptScore W2151122755C509974204 @default.
• W2151122755 hasConceptScore W2151122755C71924100 @default.
• W2151122755 hasLocation W21511227551 @default.
• W2151122755 hasOpenAccess W2151122755 @default.
• W2151122755 hasPrimaryLocation W21511227551 @default.
• W2151122755 hasRelatedWork W2002120878 @default.
• W2151122755 hasRelatedWork W2003938723 @default.
• W2151122755 hasRelatedWork W2047967234 @default.
• W2151122755 hasRelatedWork W2118496982 @default.
• W2151122755 hasRelatedWork W2364998975 @default.
• W2151122755 hasRelatedWork W2369162477 @default.
• W2151122755 hasRelatedWork W2439875401 @default.
• W2151122755 hasRelatedWork W4220908969 @default.
• W2151122755 hasRelatedWork W4238867864 @default.
• W2151122755 hasRelatedWork W2525756941 @default.
• W2151122755 hasVolume "14" @default.
• W2151122755 isParatext "false" @default.
• W2151122755 isRetracted "false" @default.
• W2151122755 magId "2151122755" @default.
• W2151122755 workType "article" @default.